Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium

被引：0

作者：

Zucchini, Giorgia ^{[1
]}

Montemurro, Filippo ^{[1
]}

机构：

[1] Candiolo Canc Inst FPO IRCCS, Invest Clin Oncol INCO, Str Prov 142, I-10060 Candiolo, Torino, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2017年 / 18卷 / 09期

关键词：

Hormone-receptor; endocrine therapy; tamoxifen; aromatase inhibitors; gene-expression analysis; genomic alterations; fulvestrant; everolimus; buparlisib; ADJUVANT ENDOCRINE THERAPY; POSTMENOPAUSAL WOMEN; PHASE-III; DOUBLE-BLIND; PLACEBO; TRIAL; FULVESTRANT; MULTICENTER; RESISTANT;

D O I：

10.1080/14656566.2017.1328500

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The San Antonio Breast Cancer Symposium is considered one of the most influential international meetings focusing on breast cancer management, covering several areas of study from basic research to clinical practice topics. a number of oral presentations addressing hormone receptor-positive breast cancer brought new data about critical subjects like the optimal duration of adjuvant endocrine therapy, new prognostic markers and their potential role in guiding adjuvant treatment choices, new insights into genomic alterations acquired during the metastatic process, and pharmacologic strategies to overcome resistance to endocrine therapy. This article aims at summarizing some of the presentations that, in our opinion, are expected to have an impact on clinical practice and research programs in this patient population.

引用

页码：853 / 855

页数：3

共 17 条

[1] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[2] Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05) [J].

Blok, E. J. ;

van de Velde, C. J. H. ;

Kranenbarg, E. M. Meershoek-Klein ;

Putter, H. ;

van den Bosch, J. ;

Maartense, E. ;

van Leeuwen-Stok, A. E. ;

Liefers, G. J. ;

Nortier, J. W. R. ;

Rutgers, E. J. T. ;

Kroep, J. R. .

CANCER RESEARCH, 2017, 77

[3] Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression [J].

Burstein, Harold J. ;

Lacchetti, Christina ;

Anderson, Holly ;

Buchholz, Thomas A. ;

Davidson, Nancy E. ;

Gelmon, Karen E. ;

Giordano, Sharon H. ;

Hudis, Clifford A. ;

Solky, Alexander J. ;

Stearns, Vered ;

Winer, Eric P. ;

Griggs, Jennifer J. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) :1689-U250

[4] Whole exome and transcriptome sequencing of resistant ER plus metastatic breast cancer [J].

Cohen, O. ;

Kim, D. ;

Oh, C. ;

Waks, A. ;

Oliver, N. ;

Helvie, K. ;

Marini, L. ;

Rotem, A. ;

Lloyd, M. ;

Stover, D. ;

Adalsteinsson, V. ;

Freeman, S. ;

Ha, G. ;

Cibulskis, C. ;

Anderka, K. ;

Tamayo, P. ;

Johannessen, C. ;

Krop, I. ;

Garraway, L. ;

Winer, E. ;

Lin, N. ;

Wagle, N. .

CANCER RESEARCH, 2017, 77

[5] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].

Cristofanilli, Massimo ;

Turner, Nicholas C. ;

Bondarenko, Igor ;

Ro, Jungsil ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Zhang, Ke ;

Theall, Kathy Puyana ;

Jiang, Yuqiu ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Slamon, Dennis .

LANCET ONCOLOGY, 2016, 17 (04) :425-439

[6] BELLE-3: A phase III study of buparlisib plus fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment [J].

Di Leo, A. ;

Lee, K. Seok ;

Ciruelos, E. ;

Lonning, P. ;

Janni, W. ;

O'Regan, R. ;

Reynier, M-A Mouret ;

Kalev, D. ;

Egle, D. ;

Csoszi, T. ;

Bordonaro, R. ;

Decker, T. ;

Tjan-Heijnen, V. C. ;

Blau, S. ;

Schirone, A. ;

Weber, D. ;

El-Hashimy, M. ;

Dharan, B. ;

Sellami, D. ;

Bachelot, T. .

CANCER RESEARCH, 2017, 77

[7] Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers [J].

Finn, Richard S. ;

Aleshin, Alexey ;

Slamon, Dennis J. .

BREAST CANCER RESEARCH, 2016, 18

[8] Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline [J].

Harris, Lyndsay N. ;

Ismaila, Nofisat ;

McShane, Lisa M. ;

Andre, Fabrice ;

Collyar, Deborah E. ;

Gonzalez-Angulo, Ana M. ;

Hammond, Elizabeth H. ;

Kuderer, Nicole M. ;

Liu, Minetta C. ;

Mennel, Robert G. ;

Van Poznak, Catherine ;

Bast, Robert C. ;

Hayes, Daniel F. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (10) :1134-+

[9] Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202) [J].

Henry, N. L. ;

Unger, J. M. ;

Schott, A. F. ;

Fehrenbacher, L. ;

Flynn, P. J. ;

Prow, D. ;

Sharer, C. W. ;

Lew, D. L. ;

Moseley, A. ;

Fisch, M. J. ;

Moinpour, C. ;

Hershman, D. L. ;

Wade, J. L., III .

CANCER RESEARCH, 2017, 77

[10] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer [J].

Hortobagyi, G. N. ;

Stemmer, S. M. ;

Burris, H. A. ;

Yap, Y. -S. ;

Sonke, G. S. ;

Paluch-Shimon, S. ;

Campone, M. ;

Blackwell, K. L. ;

Andre, F. ;

Winer, E. P. ;

Janni, W. ;

Verma, S. ;

Conte, P. ;

Arteaga, C. L. ;

Cameron, D. A. ;

Petrakova, K. ;

Hart, L. L. ;

Villanueva, C. ;

Chan, A. ;

Jakobsen, E. ;

Nusch, A. ;

Burdaeva, O. ;

Grischke, E. -M. ;

Alba, E. ;

Wist, E. ;

Marschner, N. ;

Favret, A. M. ;

Yardley, D. ;

Bachelot, T. ;

Tseng, L. -M. ;

Blau, S. ;

Xuan, F. ;

Souami, F. ;

Miller, M. ;

Germa, C. ;

Hirawat, S. ;

O'Shaughnessy, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1738-1748

← 1 2 →